Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity.
The protective effects of fosfomycin and steroids on the nephrotoxicity induced by cisplatin in lung cancer patients were studied by measuring N-acetyl-beta-D-glucosaminidase (NAG) activity in 24-hour urine, creatinine clearance, serum creatinine and blood urea nitrogen as factors of nephrotoxicity. In control patients treated with anticancer drugs containing cisplatin but no supplemental fosfomycin or steroids, the 24-hour urine NAG level increased two-fold (15.5 +/- 7.5, p less than 0.01) over the pretreatment level (8.0 +/- 5.2) 3 days after anticancer therapy. Supplemental fosfomycin or steroids inhibited an increase in urinary NAG level 3 days after the anticancer therapy. There were, however, no significant changes in creatinine clearance, serum creatinine and blood urea nitrogen levels before and after anticancer and/or supplemental therapies. These results suggest the possibility that supplemental treatment with fosfomycin, like that with steroids, reduces cisplatin-induced nephrotoxicity, especially proximal tubular damage.
Umeki
S
S
Department of Medicine, Kawasaki Medical School, Okayama, Japan.
Watanabe
M
M
Yagi
S
S
Soejima
R
R
D000118:Acetylglucosaminidase / Q000652:urine; D001806:Blood Urea Nitrogen; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D003404:Creatinine; D005578:Fosfomycin / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use*; D007687:Kidney Tubules, Proximal / Q000187:drug effects*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged
D005578:Fosfomycin; D003404:Creatinine; D000118:Acetylglucosaminidase; D002945:Cisplatin; D006854:Hydrocortisone; D008775:Methylprednisolone